Ratings by Credit Suisse (Richard Law)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/15/2023 | Homology Medicines | FIXX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2023 | Olema Pharmaceuticals | OLMA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2023 | Beam Therapeutics Inc | BEAM | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2023 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2023 | CRISPR Therapeutics | CRSP | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2023 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/9/2023 | CRISPR Therapeutics | CRSP | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2023 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 3/16/2023 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2023 | Olema Pharmaceuticals | OLMA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2023 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Outperform (N/A) |
19.14 (26.05) |
36.1% | Details | |
| 2/28/2023 | Beam Therapeutics Inc | BEAM | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2023 | C4 Therapeutics | CCCC | Upgrade | Neutral (Underperform) |
6.02 (4.29) |
-28.74% | Details | |
| 2/24/2023 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2023 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2023 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/22/2023 | Editas Medicine | EDIT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/22/2023 | Olema Pharmaceuticals | OLMA | New Coverage | Outperform (N/A) |
4.16 (11.00) |
164.42% | Details | |
| 2/22/2023 | CRISPR Therapeutics | CRSP | Maintain | Neutral (N/A) |
|
Details | ||
| 12/6/2022 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/6/2022 | Kymera Therapeutics | KYMR | Downgrade | Neutral (Outperform) |
30.78 (100.46) |
226.38% | Details | |
| 12/6/2022 | Editas Medicine | EDIT | New Coverage | Neutral (N/A) |
10.25 (2.94) |
-71.32% | Details | |
| 11/8/2022 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2022 | Beam Therapeutics Inc | BEAM | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | CRISPR Therapeutics | CRSP | Maintain | Neutral (N/A) |
|
Details | ||
| 10/6/2022 | Verve Therapeutics | VERV | New Coverage | Neutral (N/A) |
36.15 (11.13) |
-69.21% | Details | |
| 8/16/2022 | Homology Medicines | FIXX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2022 | CRISPR Therapeutics | CRSP | Maintain | Neutral (N/A) |
|
Details | ||
| 6/13/2022 | Homology Medicines | FIXX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/17/2022 | Homology Medicines | FIXX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/28/2022 | Beam Therapeutics Inc | BEAM | New Coverage | Neutral (N/A) |
39.83 (35.55) |
-10.75% | Details | |
| 4/28/2022 | CRISPR Therapeutics | CRSP | New Coverage | Neutral (N/A) |
51.96 (54.90) |
5.66% | Details |
